US69012T3059 - Common Stock
OUTLOOK THERAPEUTICS INC
NASDAQ:OTLK (5/9/2024, 7:10:31 PM)
After market: 8.11 +0.38 (+4.92%)7.73
-0.27 (-3.37%)
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 24 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The firm's product candidate, ONS-5010, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti- Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The firm sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
OUTLOOK THERAPEUTICS INC
485 Route 1 South, Building F, Suite 320
Iselin NEW JERSEY 08852
P: 16096193990
CEO: Lawrence A. Kenyon
Employees: 24
Website: https://outlooktherapeutics.com/
ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J.,...
Here you can normally see the latest stock twits on OTLK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: